IGM Biosciences (IGMS) Q2 2024 earnings summary

Executive summary

• IGM Biosciences is a clinical-stage biotech focused on IgM antibody therapeutics for cancer and autoimmune diseases, with a proprietary technology platform and ongoing Phase 1 trials for multiple candidates.

• The company deprioritized hematologic oncology and certain other programs in December 2023, focusing on colorectal cancer and autoimmune indications.

• The Sanofi collaboration now focuses exclusively on immunology targets after Sanofi terminated oncology target development in June 2024.

• Completed enrollment of 127 patients in aplitabart colorectal cancer trial, exceeding target.

• Cleared first two dose cohorts in imvotamab rheumatoid arthritis and first cohort in systemic lupus erythematosus trials.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $256.4 million as of June 30, 2024, down from $337.7 million at December 31, 2023.

• Collaboration revenue was $1.3 million for Q2 2024, up from $0.4 million in Q2 2023, due to a $0.8 million cumulative catch-up from the Sanofi refocusing.

• Net loss for Q2 2024 was $47.9 million ($0.79/share), compared to $64.4 million ($1.43/share) in Q2 2023.

• Research and development expenses for Q2 2024 were $42.0 million, down from $55.7 million in Q2 2023.

• General and administrative expenses for Q2 2024 were $10.6 million, down from $13.0 million in Q2 2023.

Outlook and guidance

• Management expects continued operating losses and increased expenses as research and development activities progress.

• Expects full year 2024 GAAP operating expenses of $210–$220 million, including ~$40 million in stock-based compensation.

• Projects year-end 2024 cash and investments of ~$180 million, sufficient to fund operations into Q2 2026.

• Top-line PFS results from aplitabart colorectal cancer trial expected by end of Q1 2025.

• Current cash resources are expected to fund operations for at least one year past the financial statement issuance date.